SELLAS Life Sciences Nears Pivotal Trial Readout As Leukemia Pipeline Progresses

All NewsMay 13, 2026

SELLAS Life Sciences reports wider Q1 loss as REGAL Phase 3 AML trial nears key data readout and SLS009 advances in early-line studies.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT